Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

The QIDP designation for brilacidin thanks to Dr Alexander the new COO was the catalyst for the tremendous price increase since Dec8. This was great "news" that brought many new investors in. FDA brilacidin P3 would have been the next leg up. As far as financing yes they have shelf offering that could cause dilution without a corporate partner. Been through an Aspire deal and saw share price go from 2.20 to 1.60 with a lot of angst from a number of board members. I understand we are farther along in testing and with a multi-billion dollar drug portfolio potential. But in the short term is where I'm concerned. If someone has the answer to this please expound. IMO